[Two U.S. experts discuss the consequences of the "Shingles Prevention Study". Is senior vaccination worthwhile in the practice?].
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D006562:Herpes Zoster / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D014645:Herpesvirus 3, Human / Q000276:immunology*; D022283:Herpesvirus Vaccines / Q000008:administration & dosage*; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D051474:Neuralgia, Postherpetic / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D014611:Vaccination
D000998:Antiviral Agents; D022283:Herpesvirus Vaccines; D010919:Placebos